+

WO1999023092A3 - 3-aminoalkylamino- 2h-1,4-benzoxazines et 3-aminoalkylamino- 2h-1,4-benzothiazines constituant des ligands specifiques d'un sous-type de recepteur de la dopamine - Google Patents

3-aminoalkylamino- 2h-1,4-benzoxazines et 3-aminoalkylamino- 2h-1,4-benzothiazines constituant des ligands specifiques d'un sous-type de recepteur de la dopamine Download PDF

Info

Publication number
WO1999023092A3
WO1999023092A3 PCT/US1998/022936 US9822936W WO9923092A3 WO 1999023092 A3 WO1999023092 A3 WO 1999023092A3 US 9822936 W US9822936 W US 9822936W WO 9923092 A3 WO9923092 A3 WO 9923092A3
Authority
WO
WIPO (PCT)
Prior art keywords
zines
benzoxa
aminoalkylamino
thia
pharmaceutical compositions
Prior art date
Application number
PCT/US1998/022936
Other languages
English (en)
Other versions
WO1999023092A2 (fr
Inventor
Xiao-Shu He
Original Assignee
Neurogen Corp
He Xiao Shu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurogen Corp, He Xiao Shu filed Critical Neurogen Corp
Priority to CA002307905A priority Critical patent/CA2307905A1/fr
Priority to JP2000518963A priority patent/JP2001521935A/ja
Priority to EP98956310A priority patent/EP1027347A2/fr
Priority to AU12863/99A priority patent/AU1286399A/en
Publication of WO1999023092A2 publication Critical patent/WO1999023092A2/fr
Publication of WO1999023092A3 publication Critical patent/WO1999023092A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne des composés représentés par la formule générale (I) ou certains de leurs sels d'addition acides pharmaceutiquement admis. En l'occurrence, Ar est aryle ou hétéroaryle. R1 et R2, qui sont identiques ou différents, sont des substituants organiques ou inorganiques. R5 est hydrogène ou C1-C6 alkyle. W est CH ou azote. X est oxygène ou soufre. Enfin, A est un groupe alkylène. Se liant sélectivement avec une affinité élevée au récepteur de sous-type D4 de la dopamine, ces composés conviennent particulièrement au traitement de divers troubles neurophychologiques.
PCT/US1998/022936 1997-10-31 1998-10-28 3-aminoalkylamino- 2h-1,4-benzoxazines et 3-aminoalkylamino- 2h-1,4-benzothiazines constituant des ligands specifiques d'un sous-type de recepteur de la dopamine WO1999023092A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002307905A CA2307905A1 (fr) 1997-10-31 1998-10-28 3-aminoalkylamino- 2h-1,4-benzoxazines et 3-aminoalkylamino- 2h-1,4-benzothiazines constituant des ligands specifiques d'un sous-type de recepteur de la dopamine
JP2000518963A JP2001521935A (ja) 1997-10-31 1998-10-28 ３−アミノアルキルアミノ−２ｈ−１，４−ベンゾキシアジン及び３−アミノアルキルアミノ−２ｈ−１，４−ベンゾチアジン：ドーパミン受容体サブタイプ特定の配位子
EP98956310A EP1027347A2 (fr) 1997-10-31 1998-10-28 3-aminoalkylamino- 2h-1,4-benzoxazines et 3-aminoalkylamino- 2h-1,4-benzothiazines constituant des ligands specifiques d'un sous-type de recepteur de la dopamine
AU12863/99A AU1286399A (en) 1997-10-31 1998-10-28 3-aminoalkylamino- 2h-1,4-benzoxazines and 3-aminoalkylamino- 2h-1,4-benzothiazines: dopamine receptor subtype specific ligands

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96202297A 1997-10-31 1997-10-31
US08/962,022 1997-10-31

Publications (2)

Publication Number Publication Date
WO1999023092A2 WO1999023092A2 (fr) 1999-05-14
WO1999023092A3 true WO1999023092A3 (fr) 1999-08-05

Family

ID=25505330

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/022936 WO1999023092A2 (fr) 1997-10-31 1998-10-28 3-aminoalkylamino- 2h-1,4-benzoxazines et 3-aminoalkylamino- 2h-1,4-benzothiazines constituant des ligands specifiques d'un sous-type de recepteur de la dopamine

Country Status (5)

Country Link
EP (1) EP1027347A2 (fr)
JP (1) JP2001521935A (fr)
AU (1) AU1286399A (fr)
CA (1) CA2307905A1 (fr)
WO (1) WO1999023092A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100255A (en) * 1998-10-28 2000-08-08 Neurogen Corporation 3-aminoalkylamino-2H-1,4-benzoxazines and 3-aminoalkylamino-2H-1,4-benzothiazines: dopamine receptor subtype specific ligands
AU2881499A (en) * 1998-02-26 1999-09-15 Neurogen Corporation Benzylpiperazinyl- and benzylpiperidinyl ethanone derivatives, their preparationand their use as dopamine d4 receptor antagonists
US6084098A (en) 1999-02-26 2000-07-04 Neurogen Corporation Benzylpiperazinyl and piperidinyl ethanone derivatives: dopamine receptor subtype specific ligands
US6284759B1 (en) 1998-09-30 2001-09-04 Neurogen Corporation 2-piperazinoalkylaminobenzo-azole derivatives: dopamine receptor subtype specific ligands
WO2000018767A2 (fr) * 1998-09-30 2000-04-06 Neurogen Corporation Derives de 2-piperazino -alkyl- aminobenzoazole: ligands specifiques du sous-type du recepteur de la dopamine
DE19941115A1 (de) * 1999-08-25 2001-03-01 Schering Ag Neue Benzoxazin- und Bezothiazin-Derivate und deren Verwendung in Arzneimitteln
EP1177792A3 (fr) 2000-07-27 2002-10-23 Pfizer Products Inc. Ligands dopamine d4 destines au traitement des troubles associees a la cherche de la nouveaute
US8411271B2 (en) 2005-12-28 2013-04-02 Nikon Corporation Pattern forming method, pattern forming apparatus, and device manufacturing method

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0186310A1 (fr) * 1984-11-28 1986-07-02 Takeda Chemical Industries, Ltd. Dérivés de 1,4-benzothiazine, leurs préparation et application

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0186310A1 (fr) * 1984-11-28 1986-07-02 Takeda Chemical Industries, Ltd. Dérivés de 1,4-benzothiazine, leurs préparation et application

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
XIAO S. H.: "A NEW SERIES OF SELECTIVE DOPAMINE D4 LIGANDS:", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 7, no. 18, 1997, GB, pages 2399 - 2402, XP004136452 *

Also Published As

Publication number Publication date
AU1286399A (en) 1999-05-24
WO1999023092A2 (fr) 1999-05-14
JP2001521935A (ja) 2001-11-13
EP1027347A2 (fr) 2000-08-16
CA2307905A1 (fr) 1999-05-14

Similar Documents

Publication Publication Date Title
MXPA05003193A (es) Compuesto de adenina novedoso y uso del mismo.
DE60015927D1 (en) Phenylharnstoff und phenylthioharnstoffderivate
CA2318349A1 (fr) Oestrone sulfamate inhibant l'oestrone sulfatase, compositions pharmaceutiques associees et methodes d'utilisation
AU8794291A (en) New oxazolopyridine derivatives, processes for preparing these and pharmaceutical compositions containing them
TW200510381A (en) Novel 2-pyridinecarboxamide derivatives
IL154893A0 (en) Aliphatic nitrogen-containing cyclic compounds, methods for the preparation thereof and pharmaceutical compositions containing the same
CA2247443A1 (fr) Derives d'acide 4-hydroxy-phenylalcanoique substitue possedant une activite agoniste envers ppar-gamma
HUP0004529A2 (hu) VLA-4 által mediált leukocita adhéziót gátló szulfonilezett dipeptid-származékok, ezeket tartalmazó gyógyászati készítmények, valamint alkalmazásuk
CA2064815A1 (fr) Composes heterocycliques therapeutiques
GB9803226D0 (en) Chemical compounds
NZ330973A (en) Azolobenzazepine derivatives as neurologically active agents
CA2203237A1 (fr) Derives d'aminotetrazole utiles en tant qu'inhibiteurs de la monoxyde d'azote synthetase
IL145759A0 (en) Amine derivatives and pharmaceutical compositions containing the same
EP1719761A4 (fr) Nouveau compose heterocyclique
DE3876813D1 (de) 3(2h)pyridazinon, verfahren zu dessen herstellung und dieses enthaltendes mittel gegen srs-a.
WO2000018769A3 (fr) Composes indolo[2,1-b]quinazole-6,12-dione antipaludiques et leurs modalites d'utilisation
AU2267495A (en) Benzamide derivatives as vasopressin antagonists
NO180196C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive amino- og nitroholdige, tricykliske forbindelser
NO20003773L (no) Syklobutenderivater, deres fremstilling og deres terapeutiske anvendelser
HUP0105105A2 (hu) Gyulladásgátló hatású makrolidok és ezeket tartalmazó gyógyszerkészítmények
MY117092A (en) Chemotherapeutic pyrrolocarbazole derivatives
WO1999023092A3 (fr) 3-aminoalkylamino- 2h-1,4-benzoxazines et 3-aminoalkylamino- 2h-1,4-benzothiazines constituant des ligands specifiques d'un sous-type de recepteur de la dopamine
WO2002007677A3 (fr) Utilisation de derives d'acide valproique et d'amides d'acide 2-valproenique pour le traitement de la manie en cas de desordre bipolaire
EP1550651A4 (fr) Derive glycerol
CA2247946A1 (fr) Composition anticachexique

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: PA/A/2000/003954

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2307905

Country of ref document: CA

Ref document number: 2307905

Country of ref document: CA

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2000 518963

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 1998956310

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 98812701.6

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 1998956310

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1998956310

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载